samedan logo
 
 
 
spacer
home > ebr > autumn 2018 > applying affimers
PUBLICATIONS
European Biopharmaceutical Review

Applying Affimers

Pharmacokinetic (PK) assays are a key component of drug development and clinical follow-up processes, with the global PK assay service market currently valued at US $652.8 million (1). Results from PK assays are critical in all phases of drug development, and numerous decisionmaking milestones in drug development programmes rely, at least in part, on PK assay results and the exposure-response relationships based on pharmacodynamic (PD) endpoints or clinical endpoints. Companies are increasingly using data from drug monitoring assays at all stages of the development pipeline to enhance the productivity and efficiency of new drug development processes (2).

Both PK and PD assays require critical reagents (eg, anti-drug reagents/anti-idiotypic binders) that can specifically and accurately measure the drug in plasma and tissues. Sensitive and reproducible PK assays are required as part of the complex and lengthy development process for new therapeutic molecules. These drug monitoring assays must be well-characterised, fully validated, and documented to yield reliable results compliant with the necessary regulatory standards.

Antibodies currently represent the ‘gold standard’ of affinity reagents, and, while traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable, these can be limited by development speed, complexity to produce on an industrial scale, and lotto- lot variation in assay performance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Amanda Nicholl is Senior Assay Development Scientist at Avacta, where she applies her experience in molecular and cellular biology in both academic and industrial environments to develop assays and generate data to exemplify the use of affimer technology.
spacer
Dr Amanda Nicholl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement